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Should young patients with high-risk multiple myeloma be offered 
allogeneic transplants? A vote in favour
Sebastian Giebel
The prognosis of patients with multiple myeloma has improved markedly over the last two decades. Despite that, 
allogeneic hematopoietic stem cell transplantation remains the only treatment option with curative potential. There-
fore it should be considered for younger patients, especially those with high-risk disease as defined based on revised 
international scoring system. A decision to use transplantation, as well as the choice of conditioning regimen should 
be personalized, taking into account a particular center’s experience.
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The prognosis of patients with multiple myeloma (MM) 
has improved markedly over the last two decades [1]. This is 
due to the introduction of immunomodulatory drugs such 
as thalidomide, lenalidomide, pomalidomide and prote-
asome inhibitors: bortezomib, carfilzomib. Administration 
of these drugs at the induction stage allows for obtaining 
a large percentage of total and partial remissions. On the 
other hand, the depth of response translates into a longer 
time of progression-free survival (PFS) and overall survival 
(OS) [1]. This effect can be enhanced by applying high-dose 
therapy, usually melphalan at a total dose of 200 mg/m2 of 
body surface area, which requires support with autologous 
hematopoietic cell transplantation (autoHCT). AutoHCT 
remains the standard of management in younger patients, 
conventionally under 65 years of age [2]. The results of some 
clinical trials indicate that dual autoHCT may contribute to 
a further increase in OS time, although this issue remains 
controversial [3]. The results of meta-analysis of three clinical 
trials also indicate that maintenance with lenalidomide has 
a beneficial effect on survival [4].
Despite significant progress in pharmacotherapy, MM 
is still considered an untreatable disease. Following initial 
response, progression almost inevitably occurs, and the 
effectiveness of subsequent treatment lines is decreasing. 
The prognosis of patients with PFS and OS can be estimated 
using a Revised International Scoring System (R-ISS) [5]. It 
takes into account the concentration of β-2-microglobulin 
and serum activity of lactate dehydrogenase, as well as 
karyotype features of neoplastic cells. The median PFS for 
patients with R-ISS I, II and III values was shown to be 66, 
42 and 29 months, respectively [5]. In turn the median OS 
in case of R-ISS = III is 42 months [5]. In a more recent ana-
lysis by Kastritis et al. this median was only 27 months [6]. 
While these survival times may be considered satisfactory 
for elderly patients, they are difficult to accept for younger 
ones. Although MM is a disease typical of older age, it is also 
diagnosed in persons being 30 or even 20 year old. Jurczy-
szyn et al. published an analysis covering 173 patients aged 
21–40 years and 916 patients aged 41–60 years [7]. The OS 
probability after 10 years was 56% and 39%, respectively. 
However, it was significantly worse in patients with ISS = II 
or III, without differences depending on the age group. Mo-
reover, it has been demonstrated that in younger patients 
unfavorable cytogenetic changes are more frequent [7]. 
The above data indicate the need to look for a more radical 
treatment strategy for younger patients with MM, especially 
if they have risk factors associated with shorter expected 
time of PFS and OS.
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The only therapeutic method giving a chance to cure 
MM patients is allogeneic hematopoietic cell transplantation 
(alloHCT). It offers a possibility of applying myeloablative 
doses of chemotherapy or irradiation, called conditioning, 
without the risk of cancer cell re-transplantation. The effi-
cacy of alloHCT is also a result of a graft versus myeloma 
reaction, which is caused by alloreactive T lymphocytes 
present in the transplant material. They can eliminate re-
sidual myeloma cells in the recipient’s body, contributing 
to the cure. Nowadays it is possible to identify a potential 
donor for almost every patient. These may be HLA-matched 
sibling, matched unrelated donor, but also a family donor 
matching with only one HLA haplotype.
Unfortunately, alloHCT procedure is associated with a 
very high risk of complications, including life-threatening 
ones. This applies to the toxicity of conditioning, infectious 
complications resulting from long immunosuppression, as 
well as graft versus host disease, which is an expression of 
alloreactivity of donor lymphocytes against recipient’s heal-
thy cells. In historical analyses, the risk of transplant-related 
mortality (TRM) in myeloablative-conditioned transplants 
reached 40% [8]. It should be noted, however, that these 
were patients at late stages of the disease, in which many 
therapy lines were used earlier, with numerous coexisting 
diseases. At the end of the 20th century, alternative prepa-
rative regimens of reduced intensity were developed. The 
main purpose of conditioning was to enable engraftment, 
assuming that the graft versus myeloma reaction would be 
sufficient to obtain a cure. TRM was limited considerably, 
the risk of progression was, however, significantly higher 
in comparison with myeloablative-conditioned transplants 
[8]. The next step were tandem transplantations, in which in 
the first stage autoHCT was performed in order to reduce 
the tumor mass as much as possible, and then alloHCT with 
reduced-intensity conditioning. A number of prospective 
clinical trials have been conducted comparing this strategy 
with the tandem autoHCT one. Two studies showed an ad-
vantage of auto-alloHCT over auto-autoHCT in relation to 
PFS and OS, while in the remaining five such a relationship 
was not found [9]. The meta-analysis of these studies did 
not lead to the formulation of unambiguous conclusions [9].
Taking into account historical experiences indicating 
excessive toxicity of traditional myeloablative protocols 
and insufficient effectiveness of alloHCT with reduced con-
ditioning intensity, it seems advisable to look for a “third 
route”, i.e. preparation with myeloablative potential, which, 
however, would be characterized by better tolerance. At 
Maria Skłodowska-Curie Cancer Center and Institute of On-
cology, Branch in Gliwice, a new protocol has been deve-
loped, which may satisfy these conditions. It is based on a 
tandem strategy: auto-allo-HCT. In the autoHCT procedure, 
melphalan is used at a dose of 200 mg/m2 of the body sur-
face area. After about three months, alloHCT is performed 
with bendamustine conditioning in combination with total 
marrow irradiation (TMI). The TMI is performed with helical 
tomotherapy using three fractions of 4 Gy each, i.e. a total 
of 12 Gy. This is a myeloablative dose, but focused on the 
skeleton, i.e. the natural location of MM cells. On the other 
hand, the dose for organs which are supposed to be free 
from disease, i.e. lungs, heart, liver, gastrointestinal tract is 
very limited. Initial experience of 14 patients aged 28–55 
years treated in this way points to good tolerance and lack 
of TRM, with a PFS probability of 78% after 2 years (unpu-
blished data).
To sum up, alloHCT remains the only option giving a 
chance to cure MM patients. In younger patients, indications 
should be determined on individual basis, taking into acco-
unt the risk factors of failure of conventional pharmacothe-
rapy, but also the patient’s attitudes and experience of the 
centre. It is advisable to search for forms of conditioning of 
reduced toxicity with preserved myeloablative potential. In 
the future, new forms of cellular immunotherapy, e.g. the 
use of T lymphocytes with a chimeric antigen receptor, may 
be a safer and potentially more effective alternative [10].
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